Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
Hoffmann-La Roche
National Cancer Institute (NCI)
Genmab
Seagen Inc.
University of California, Davis
Hoffmann-La Roche
M.D. Anderson Cancer Center
Erasca, Inc.
Bayer
Pfizer
Boehringer Ingelheim
M.D. Anderson Cancer Center
Replimune Inc.
University of Oklahoma
USWM, LLC (dba US WorldMeds)
University of California, Davis
City of Hope Medical Center
Novartis
M.D. Anderson Cancer Center
Pfizer
ImmunityBio, Inc.
AbbVie
M.D. Anderson Cancer Center
AgonOx, Inc.
Novartis
Bayer
M.D. Anderson Cancer Center
Amgen
Inhibrx Biosciences, Inc
Incyte Corporation
University Health Network, Toronto
NeoTX Therapeutics Ltd.
HiFiBiO Therapeutics
HiFiBiO Therapeutics
Massachusetts General Hospital
AstraZeneca
University of Pittsburgh
Tesaro, Inc.
OncoHost Ltd.
Sichuan Baili Pharmaceutical Co., Ltd.
Asher Biotherapeutics, Inc.
Valo Therapeutics Oy
Cancer Research UK
Milton S. Hershey Medical Center
Oslo University Hospital
N.N. Petrov National Medical Research Center of Oncology
Merck Sharp & Dohme LLC
Theratechnologies
The Methodist Hospital Research Institute
UNICANCER